Press releases
- Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society
- Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028
- Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests
- Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes
- Dexcom Reports First Quarter 2023 Financial Results
- Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB
- Dexcom Commends Decision to Expand CGM Medicare Coverage to Include People With Diabetes Using All Types of Insulin
- Dexcom Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 at 4:30 p.m. Eastern Time
- Dexcom Publishes Annual Sustainability Report
- Mednow Achieves Record Q2 2023 Financial Results with Quarterly Revenue of $11.3 Million; 17% Q/Q Revenue Growth and 466% Y/Y Revenue Growth; Adjusted EBITDA Improved 32% Y/Y; and Cash Flow from Operations Improved by 7% Q/Q
More ▼
Key statistics
On Wednesday, Dexcom Inc (DC4:FRA) closed at 105.42, -15.27% below its 52-week high of 124.42, set on Oct 31, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 105.42 |
---|---|
High | 105.42 |
Low | 105.42 |
Bid | -- |
Offer | -- |
Previous close | 107.78 |
Average volume | 306.92 |
---|---|
Shares outstanding | 387.64m |
Free float | 384.65m |
P/E (TTM) | 164.56 |
Market cap | 44.02bn USD |
EPS (TTM) | 0.6901 USD |
Data delayed at least 15 minutes, as of May 31 2023 07:20 BST.
More ▼